Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?

European Journal of Cancer

Volumn 45, Issue 5, 2009, Pages 837-842

  Jakubowska, Anna ^a   Jaworska, Katarzyna ^a   Cybulski, Cezary ^a   Janicka, Anna ^a   Szymańska Pasternak, Jolanta ^a   Lener, Marcin ^a   Narod, Steven A ^b   Lubiński, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Centre for Research on Women's Health   (Canada)

Author keywords

BRCA1 mutation; Breast cancer risk; ITGB3; MTHFR; PHB; RAD51; Single nucleotide polymorphism; TGFB1; VEGF

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILIAL CANCER; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; ITGB3 GENE; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MTHFR GENE; ONCOGENE; PHB GENE; POLAND; PRIORITY JOURNAL; RAD51 GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TGFB1 GENE; VEGF GENE;

ADULT; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 61349162979     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.021     Document Type: Article

References (24)

1. Górski B., Jakubowska A., Huzarski T., et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110 (2004) 683-686
2. Górski B., Byrski T., Huzarski T., et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66 (2000) 1963-1968
3. Górski B., Cybulski C., Huzarski T., et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92 (2005) 19-24
4. Jakubowska A., Gronwald J., Górski B., et al. The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res Treat 104 (2007) 67-74
5. Jakubowska A., Gronwald J., Menkiszak J., et al. The RAD51 135 G > C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 16 (2007) 270-275
6. Jakubowska A., Gronwald J., Menkiszak J., et al. Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. J Med Genet 44 (2007) 408-411
7. Jakubowska A., Gronwald J., Menkiszak J., et al. VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262 (2008) 71-76
8. Jakubowska A., Gronwald J., Menkiszak J., et al. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 104 (2007) 299-308
9. Jakubowska A., Gronwald J., Menkiszak J., et al. Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3′ untranslated region polymorphism. BMC Cancer 8 (2008) 90
10. Jupe E.R., Badgett A.A., Neas B.R., et al. Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility. Lancet 357 (2001) 1588-1589
11. Spurdle A.B., Hopper J.L., Chen X., et al. Prohibitin 3′ untranslated region polymorphism and breast cancer risk in Australian women. Lancet 360 (2002) 925-926
12. Campbell I.G., Allen J., and Eccles D.M. Prohibitin 3′ untranslated region polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12 (2003) 1273-1274
13. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 (1997) 1505-1510
14. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol 16 (1998) 1642-1649
15. White J.J., Ledbetter D.H., Eddy Jr. R.L., et al. Assignment of the human prohibitin gene (PHB) to chromosome 17 and identification of a DNA polymorphism. Genomics 11 (1991) 228-230
16. Nagai M.A., Yamamoto L., Salaorni S., et al. Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes Chromosomes Cancer 11 (1994) 58-62
17. Rastogi S., Joshi B., Dasgupta P., Morris M., Wright K., and Chellappan S. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 26 (2006) 4161-4171
18. Wang S., Nath N., Adlam M., and Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18 (1999) 3501-3510
19. Fusaro G., Dasgupta P., Rastogi S., Joshi B., and Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 278 (2003) 47853-47861
20. Wang S., Zhang B., and Faller D.V. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J 21 (2002) 3019-3028
21. Gamble S.C., Chotai D., Odontiadis M., et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 26 (2007) 1757-1768
22. Sun L., Liu L., Yang X.J., and Wu Z. Akt binds prohibitin 2 and relieves its repression of MyoD and muscle differentiation. J Cell Sci 117 (2004) 3021-3029
23. He B., Feng Q., Mukherjee A., et al. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol 22 (2008) 344-360
24. Fan S., Wang J., Yuan R., et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284 (1999) 1354-1356